DES self-assessment : a guide to understanding your risk for DES exposure
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields



Document Data
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page


DES self-assessment : a guide to understanding your risk for DES exposure

Filetype[PDF-327.80 KB]



  • Corporate Authors:
  • Description:
    1938—1971: DESprescribedforpregnantwomen

    1971—2002: Research identifies long-term DES health risks

    2003: CDC’s DESUPDATE begins...

    Diethylstilbestrol (DES) is a synthetic estrogen that was developed to supplement a woman’s natural estrogen production. First prescribed by physicians in 1938 for women who experienced miscarriages or premature deliveries, DES was originally considered effective and safe for both the pregnant woman and the developing baby. In the United States, an estimated 5—10 million persons were exposed to DES during 1938—1971, including women who were prescribed DES while pregnant and the female and male children born of these pregnancies. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.

    No known medical test (such as blood, urine or skin analysis) has been developed that can detect DES exposure. However, the DES Self-Assessment Guide is designed to help you assess whether you might have been exposed to DES.

  • Subjects:
  • Document Type:
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at